Results 251 to 260 of about 70,680 (286)

Innovation Policy and the Economy, Volume 6 [PDF]

open access: yes
Adrian H. B. Gottschalk   +2 more
core  

BIOPHARMACEUTICALS

2017
Biopharmaceuticals are primarily therapeutic proteins developed to perform specific functions by acting on the disease pathophysiology. Compared with low-molecular chemically synthesized drugs, production of biopharmaceuticals is much more complex and routes of administration and pharmacokinetics differ.
Gils, Ann   +4 more
openaire   +2 more sources

Biopharmaceutical formulation

Current Opinion in Biotechnology, 2000
The rapid maturation of the field of biopharmaceutical formulation is the result of the simultaneous development of a thermodynamic mechanism for protein-solvent interaction and identification of natural chemicals employed by nature to stabilize proteins in response to environmental stresses.
openaire   +2 more sources

Biopharmaceutics

2015
Biopharmaceutics is the field that investigates and describes everything that happens with a medicinal product and the active substance between the moment of administration, the moment it exerts its action and the moment it is eliminated from the body. Biopharmaceutics connects the physico-chemical properties of an active substance and its dosage form ...
Frijlink, Henderik W.   +2 more
openaire   +1 more source

Veterinary-based biopharmaceuticals

Trends in Biotechnology, 2012
The veterinary vaccine market is forecast to grow consistently over the next several years [12xVeterinary Vaccines Market to 2017. GBI Research. See all References[12]. Moreover, the vaccine market for companion animals is growing more rapidly than any other animal health sector [13xSee all References[13].
Michael P, Ryan, Gary, Walsh
openaire   +2 more sources

Biopharmaceutical benchmarks 2014

Nature Biotechnology, 2014
Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a dramatic slowdown in recent years.
openaire   +2 more sources

Theranostic of biopharmaceuticals

Pharmacology & Therapeutics, 2017
Monoclonal antibodies (mAbs) and fusion proteins with an Fc portion of immunoglobulin G (IgG) are emblematic of the remarkable expansion of biopharmaceuticals. Despite their biological origin, these products display an interindividual variability in their efficacy and/or side effects, which must be taken into consideration.
Benjamin, Chaigne, Hervé, Watier
openaire   +2 more sources

Home - About - Disclaimer - Privacy